Myovant Sciences
2000 Sierra Point Parkway, Suite 900
Brisbane, CA 94005
United States
Tel: 650-392-0222
Website: https://www.myovant.com/
About Myovant Sciences
We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.
111 articles with Myovant Sciences
-
Myovant Sciences to Present at Upcoming Investor Conferences - June 01, 2021
6/1/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences
-
The U.S. FDA is starting off the summer months with a busy week after the Memorial Day holiday in the U.S. Here’s a look.
-
The U.S. FDA has granted approval to MYFEMBREE, Myovant Sciences, and Pfizer’s once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
-
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
5/21/2021
CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroids Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe Relugolix combination tablet for uterine fibroids is also under U.S. FDA review with a target action date of June 1, 2021
-
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
5/11/2021
Company remains well-capitalized with cash, cash equivalents, marketable securities and committed funding of $726.2 million as of March 31, 2021
-
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
5/4/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2020, ended March 31, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on May 11, 2021.
-
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
4/12/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)
-
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
4/5/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021.
-
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
3/29/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of advanced prostate cancer.
-
Clinical Catch-Up: March 22-26
3/29/2021
There was a fair amount of clinical trial news last week. Here’s a look. -
Myovant Sciences and Pfizer announced positive results from the Phase III LIBERTY trial of relugolix combination therapy in women with uterine fibroids.
-
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
3/24/2021
Myovant Sciences and Pfizer Inc. announced positive data from the Phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy in women with uterine fibroids.
-
Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
3/23/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of its Forward for Health Equity grants
-
Clarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually.
-
Myovant Sciences to Present at Upcoming Investor Conferences - Feb 22, 2021
2/22/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Feb 17, 2021
2/17/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced that it approved equity awards for 7 new employees with a grant date of February 16, 2021 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
2/17/2021
LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline Achieved six of seven key secondary endpoints including reduction of pain Bone mineral density maintained at levels comparable to placebo Data were included in U.S. New Drug Application for relugolix combination tablet for uterine fibroids
-
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
2/16/2021
HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences, a healthcare company focused on redefining care for women and for men, launched “Voices of Periods,” a storytelling initiative to elevate conversations about menstrual health by sharing diverse, personal stories of the real-life impact of menstrual stigma.
-
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
2/11/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the third quarter of fiscal year 2020.